Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pimecrolimus (Novartis).

R E Schopf1

  • 1Department of Dermatology, Johannes Gutenberg University, 55101 Mainz, Germany. schopf@hautklinik.klinik.uni-mainz.de

Idrugs : the Investigational Drugs Journal
|August 23, 2005
PubMed
Summary

Pimecrolimus, a T-cell and mast cell inhibitor, is being developed for psoriasis and dermatitis. Clinical trials are progressing, with significant sales predicted for this promising therapeutic agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An exploratory, prospective, open-label trial of ingenol mebutate gel 0.05% for the treatment of external anogenital warts.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016
Same author

Ingenol mebutate gel is effective against anogenital warts - a case series in 17 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015
Same author

Interactions between epidermal cells and lymphocytes in psoriasis.

Immunology today·2014
Same author

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

The British journal of dermatology·2013
Same author

[Neurotrophic ulcer as late sequela of trigeminal nerve excision].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2002

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Pimecrolimus is an ascomycin macrolactam derivative.
  • It functions as an inhibitor of T-cell and mast cell activation.
  • Novartis is developing pimecrolimus for potential therapeutic use.

Purpose of the Study:

  • To evaluate the efficacy and safety of pimecrolimus formulations.
  • To assess the potential of pimecrolimus in treating inflammatory skin conditions.

Main Methods:

  • Development of topical and oral formulations of pimecrolimus.
  • Conducting Phase II and Phase III clinical trials.
  • Monitoring patient responses and adverse events.

Main Results:

  • Topical pimecrolimus reached Phase III trials by December 1998.
  • Oral pimecrolimus was in Phase II trials by December 1998.
  • Phase III trials for atopic dermatitis commenced in July 1999.

Conclusions:

  • Pimecrolimus demonstrates potential for treating psoriasis and allergic dermatitis.
  • Ongoing clinical trials indicate progression towards therapeutic application.
  • Financial projections suggest significant market potential for pimecrolimus.

Related Experiment Videos